ArticleBrain, behavior, & immunity - health2024
Brain ventricle and choroid plexus morphology as predictor of treatment response in major depression: Findings from the EMBARC study.
Article in Brain, behavior, & immunity - health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Glymphatic Dysfunction and Related Brain Structure Changes in Major Depressive Disorder: Effects of Glymphatic Function in Mediating Neuroinflammation.Psychiatry investigation · 2026Article
- Glymphatic system-dependent mechanisms connecting sudden sensorineural hearing loss to cognitive and emotional impairments.Brain imaging and behavior · 2026Article
- Choroid plexus enlargement is associated with poor functional status in cerebral small vessel disease via reduced DTI-ALPS index: a 5T MRI study.Quantitative imaging in medicine and surgery · 2026Article
- Brain Structural Changes and Cognitive-Clinical Profiles in Late-Onset Unexplained Epilepsy.Neurology · 2026Article
- Linking inflammatory and structural neuroimaging biomarkers in treatment-resistant depression: Current evidence and emerging hypotheses.Neuroscience applied · 2026Review
- Discovery of Personalized Treatment for Immuno-Metabolic Depression-Focus on 11beta Hydroxysteroid Dehydrogenase Type 2 (11betaHSD2) and Toll-like Receptor 4 (TLR4) Inhibition with Enoxolone.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lateral Ventricular Enlargement and Asymmetry and Myelin Content Imbalance in Individuals With Bipolar and Depressive Disorders: Clinical and Research Implications.Bipolar disorders · 2025Article
- Abnormal choroid plexus, hippocampus, and lateral ventricles volumes as markers of treatment-resistant major depressive disorder.Psychiatry and clinical neurosciences · 2025Article
- Continuum topological derivative - A novel application tool for segmentation of CT and MRI images.Neuroimage. Reports · 2024Article
- Treatment withNutrients · 2024Article
- Brain ventricle and choroid plexus morphology as predictor of treatment response in major depression: Findings from the EMBARC study.Brain, behavior, & immunity - health · 2024Article
- Brain Ventricle and Choroid Plexus Morphology as Predictor of Treatment Response: Findings from the EMBARC Study.Research square · 2023Article
Corrections and comments
- Update of
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Recent observations suggest a role of the volume of the cerebral ventricle volume, corpus callosum (CC) segment volume, in particular that of the central-anterior part, and choroid plexus (CP) volume for treatment resistance of major depressive disorder (MDD). An increased CP volume has been associated with increased inflammatory activity and changes in the structure of the ventricles and corpus callosum. We attempt to replicate and confirm that these imaging markers are associated with clinical outcome in subjects from the EMBARC study, as implied by a recent pilot study. The EMBARC study is a placebo controlled randomized study comparing sertraline vs. placebo in patients with MDD to identify biological markers of therapy resistance. Association of baseline volumes of the lateral ventricles (LVV), choroid plexus volume (CPV) and volume of segments of the CC with treatment response after 4 weeks treatment was evaluated. 171 subjects (61 male, 110 female) completed the 4 week assessments; gender and age were taken into account for this analyses. As previously reported, no treatment effect of sertraline vs. placebo was observed, therefore the study characterized prognostic markers of response in the pooled population. Change in depression severity was identified by the ratio of the Hamilton-Depression rating scale 17 (HAMD-17) at week 4 divided by the HAMD-17 at baseline (HAMD-17 ratio). Volumes of the lateral ventricles and choroid plexi were positively correlated with the HAMD-17 ratio, indication worse outcome with larger ventricles and choroid plexus volumes, whereas the volume of the central-anterior corpus callosum was negatively correlated with the HAMD-17 ratio. Responders (n = 54) had significantly smaller volumes of the lateral ventricles and CP compared to non-responders (n = 117), whereas the volume of mid-anterior CC was significantly larger compared to non-responders (n = 117), confirming our previous findings. In an exploratory way associations between enlarged LVV and CPV and signs of lipid dysregulation were observed. In conclusion, we confirmed that volumes of lateral ventricles, choroid plexi and the mid-anterior corpus callosum are associated with clinical improvement of depression and may be indicators of metabolic/inflammatory activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.